Duration of Atrial Fibrillation Persistence: Implications for Recurrence Risk after Catheter Ablation and Efficacy of Additional Substrate Ablation
Yasuharu Matsunaga-Lee,Koichi Inoue,Nobuaki Tanaka,Masaharu Masuda,Tetsuya Watanabe,Nobuhiko Makino,Yasuyuki Egami,Takafumi Oka,Hitoshi Minamiguchi,Miwa Miyoshi,Masato Okada,Takashi Kanda,Yasuhiro Matsuda,Masato Kawasaki,Shodai Kawanami,Kohei Ukita,Akito Kawamura,Koji Yasumoto,Masaki Tsuda,Naotaka Okamoto,Masamichi Yano,Masami Nishino,Akihiro Sunaga,Yohei Sotomi,Tomoharu Dohi,Daisaku Nakatani,Shungo Hikoso,Yasushi Sakata
DOI: https://doi.org/10.1016/j.hrthm.2024.01.053
IF: 6.779
2024-02-04
Heart Rhythm
Abstract:Background The optimal duration of atrial fibrillation (AF) persistence for predicting poor outcomes post-catheter ablation of longstanding-persistent AF (LsAF) and the best ablation strategy for these patients remain unclear. Objective We aimed to assess the impact of the duration of AF persistence on outcomes after catheter ablation of AF. Methods We analyzed the EARNEST-PVI trial data comparing pulmonary vein isolation alone (PVI- alone) and with additional ablation of linear and/or defragmentation (PVI-plus) in persistent AF (PerAF). Patients who received catheter ablation using contact force sensing catheter were enrolled in the present study. In patients with LsAF, the optimal cutoff duration of AF persistence was evaluated. Using the threshold, patients with LsAF were divided into two groups and compared with PerAF (<1 year) for arrhythmia-free survival after a 3-month blanking period. Results The optimal cutoff duration was 2.4 years. Of 458 patients, arrhythmia-free survival rates for LsAF (1-2.4 years) were comparable to PerAF (HR 1.01, 95% CI 0.67-1.52). However, LsAF (>2.4 years) had a higher recurrence risk compared to PerAF (HR 2.22, 95% CI 1.42-3.47). In LsAF (>2.4 years), the PVI-plus strategy showed advantages over the PVI-alone strategy (HR 0.36, 95% CI 0.14-0.89). However, the interaction effect between LsAF (1-2.4 years) and LsAF (>2.4 years) did not reach statistical significance (p=0.116). Conclusion While LsAF (1-2.4 years) has similar outcomes to PerAF, LsAF (>2.4 years) was linked to higher arrhythmia recurrence risks. For LsAF (>2.4 years), the PVI-plus strategy showed a potential to be superior to the PVI-alone strategy.
cardiac & cardiovascular systems